Clinical Research Directory
Browse clinical research sites, groups, and studies.
CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
Sponsor: New York Medical College
Summary
Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.
Official title: MAC-CAR: a Phase 1B/II Trial of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Autologous CD30+ CAR T Cells in Children, Adolescents and Young Adults with Poor-Risk Classical Hodgkin Lymphoma (cHL)
Key Details
Gender
All
Age Range
6 Years - 29 Years
Study Type
INTERVENTIONAL
Enrollment
21
Start Date
2024-12-01
Completion Date
2040-12-31
Last Updated
2024-10-18
Healthy Volunteers
No
Conditions
Interventions
CD30 CAR T-cell
After MAC and AutoHSCT patients will receive CD30+ CAR T-cells (Phase 1B dose level 1 - 1x108/m2 (max 2.5x108) or dose level 2 - 2x108/m2 (max 5.0 x108) 21-42 days after the AutoHSCT and the RP2D dose level obtained in the Phase IB part administered in the Phase II portion.
Locations (1)
New York Medical College
Valhalla, New York, United States